{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:44:18Z","timestamp":1740145458802,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Agents Cancer"],"DOI":"10.1186\/s13027-024-00603-5","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T10:02:56Z","timestamp":1723456976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patients with multiple myeloma infected with COVID-19 during autologous stem cell transplantation"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7899-3071","authenticated-orcid":false,"given":"Rosaria","family":"De Filippi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpaolo","family":"Marcacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Amelio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Becchimanzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9425-9026","authenticated-orcid":false,"given":"Antonio","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,12]]},"reference":[{"key":"603_CR1","unstructured":"European Centre for Disease Prevention and Control. Communicable disease threats report, 22\u201328 June 2024, week 26. 28. Jun 2024. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/communicable-disease-threats-report-22-28-june-2024-week-26 (accessed July 7, 2024)."},{"key":"603_CR2","unstructured":"Centers for Disease Control and Prevention. United States covid-19 deaths, emergency department (ED) visits, and test positivity by geographic area. 1 Jul 2024. https:\/\/covid.cdc.gov\/covid-data-tracker\/#maps_percent-covid-deaths (accessed July 7, 2024)."},{"issue":"10","key":"603_CR3","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","volume":"7","author":"F Passamonti","year":"2020","unstructured":"Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737\u201345.","journal-title":"Lancet Haematol"},{"issue":"3","key":"603_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jmii.2024.03.001","volume":"57","author":"TY Wu","year":"2024","unstructured":"Wu TY, Tsai WT, Chen KH, et al. Clinical manifestations and risk factors for COVID-19 and its severity in patients with hematological malignancies. J Microbiol Immunol Infect. 2024;57(3):403\u201313. https:\/\/doi.org\/10.1016\/j.jmii.2024.03.001.","journal-title":"J Microbiol Immunol Infect"},{"issue":"10","key":"603_CR5","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S1470-2045(20)30442-3","volume":"21","author":"LYW Lee","year":"2020","unstructured":"Lee LYW, Cazier JB, Starkey T, et al. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21(10):1309\u201316.","journal-title":"Lancet Oncol"},{"key":"603_CR6","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.3390\/ijms23063368","volume":"23","author":"S Mancuso","year":"2022","unstructured":"Mancuso S, Mattana M, Carlisi M, Santoro M, Siragusa S. Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after treatment: the paradigm of targeted therapy. Int J Mol Sci. 2022;23:3368. https:\/\/doi.org\/10.3390\/ijms23063368.","journal-title":"Int J Mol Sci"},{"key":"603_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","volume":"138","author":"G Pratt","year":"2007","unstructured":"Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol. 2007;138:563\u201379.","journal-title":"Br J Haematol"},{"key":"603_CR8","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/s41375-018-0163-4","volume":"32","author":"JLJ Heaney","year":"2018","unstructured":"Heaney JLJ, Campbell JP, Iqbal G, et al. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia. 2018;32:1727\u201338. https:\/\/doi.org\/10.1038\/s41375-018-0163-4.","journal-title":"Leukemia"},{"issue":"1","key":"603_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13027-021-00376-1","volume":"16","author":"G Marcacci","year":"2021","unstructured":"Marcacci G, Fiorentino G, Volzone F, et al. Atypical COVID-19 dynamics in a patient with mantle cell lymphoma exposed to Rituximab. Infect Agent Cancer. 2021;16(1):38. https:\/\/doi.org\/10.1186\/s13027-021-00376-1. Published 2021 Jun 2.","journal-title":"Infect Agent Cancer"},{"key":"603_CR10","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1097\/HS9.0000000000000603","volume":"5","author":"E Gaitzsch","year":"2021","unstructured":"Gaitzsch E, Passerini V, Khatamzas E, Strobl CD, Muenchhoff M, Scherer C, et al. COVID-19 in patients receiving CD20-depleting immunochemotherapy for B-cell lymphoma. Hemasphere. 2021;5:e603.","journal-title":"Hemasphere"},{"issue":"2","key":"603_CR11","doi-asserted-by":"publisher","first-page":"e13792","DOI":"10.1111\/tid.13792","volume":"24","author":"M Shahzad","year":"2022","unstructured":"Shahzad M, Chaudhary SG, Zafar MU, et al. Impact of COVID-19 in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Transpl Infect Dis. 2022;24(2):e13792. https:\/\/doi.org\/10.1111\/tid.13792.","journal-title":"Transpl Infect Dis"},{"issue":"6","key":"603_CR12","doi-asserted-by":"publisher","first-page":"e2483","DOI":"10.1002\/rmv.2483","volume":"33","author":"BA Randi","year":"2023","unstructured":"Randi BA, Higashino HR, Silva VPD, Xavier EM, Rocha V, Costa SF. COVID-19 in hematopoietic stem-cell transplant recipients: a systematic review and meta-analysis of clinical characteristics and outcomes. Rev Med Virol. 2023;33(6):e2483. https:\/\/doi.org\/10.1002\/rmv.2483.","journal-title":"Rev Med Virol"},{"key":"603_CR13","doi-asserted-by":"publisher","unstructured":"Su C, Huang L, Liang L et al. The patients with multiple myeloma were infected with COVID-19 during autologous stem cell transplantation: case report and literature review. Infect Agent Cancer. 2024;19(1):25. Published 2024 May 27. https:\/\/doi.org\/10.1186\/s13027-024-00587-2","DOI":"10.1186\/s13027-024-00587-2"},{"key":"603_CR14","doi-asserted-by":"crossref","unstructured":"van Oekelen O, Gleason CR, Agte S et al. PVI\/Seronet team. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021;39(8):1028\u20131030. https:\/\/doi.org\/10. 1016\/j. ccell. 2021. 06. 014.","DOI":"10.1016\/j.ccell.2021.06.014"},{"issue":"1","key":"603_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood.2021013429","volume":"139","author":"JC En\u00dfle","year":"2022","unstructured":"En\u00dfle JC, Campe J, Schwenger A, et al. Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma. Blood. 2022;139(1):137\u201342. https:\/\/doi.org\/10.1182\/blood.2021013429.","journal-title":"Blood"},{"issue":"11","key":"603_CR16","doi-asserted-by":"publisher","first-page":"E443","DOI":"10.1002\/ajh.26348","volume":"96","author":"S Lockmer","year":"2021","unstructured":"Lockmer S, Uttervall K, Kashif M, et al. Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and\/or immunotherapy. Am J Hematol. 2021;96(11):E443\u20136. https:\/\/doi.org\/10.1002\/ajh.26348.","journal-title":"Am J Hematol"},{"key":"603_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41408-020-00372-5","volume":"10","author":"J Mart\u00ednez-L\u00f3pez","year":"2020","unstructured":"Mart\u00ednez-L\u00f3pez J, Mateos MV, Encinas C, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J. 2020;10:103. https:\/\/doi.org\/10.1038\/s41408-020-00372-5.","journal-title":"Blood Cancer J"},{"issue":"6","key":"603_CR18","doi-asserted-by":"publisher","first-page":"e435","DOI":"10.1016\/S2352-3026(20)30124-1","volume":"7","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Management of patients with multiple myeloma during the COVID-19 pandemic. Lancet Haematol. 2020;7(6):e435\u20137. https:\/\/doi.org\/10.1016\/S2352-3026(20)30124-1.","journal-title":"Lancet Haematol"},{"issue":"6","key":"603_CR19","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/s41375-023-01920-1","volume":"37","author":"E Terpos","year":"2023","unstructured":"Terpos E, Musto P, Engelhardt M, et al. Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). Leukemia. 2023;37(6):1175\u201385. https:\/\/doi.org\/10.1038\/s41375-023-01920-1.","journal-title":"Leukemia"},{"key":"603_CR20","doi-asserted-by":"crossref","unstructured":"Cesaro S, Mikulska M, Hirsch HH, Styczynski J, Meylan S, Cordonnier C et al. Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL9). Leukemia. 2023;37:1933.","DOI":"10.1038\/s41375-023-01938-5"},{"issue":"1","key":"603_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10238-024-01381-5","volume":"24","author":"HJ Ng","year":"2024","unstructured":"Ng HJ, Alata MK, Nguyen QT, Huynh DV, Tan JY, Wong CL. Managing and treating COVID-19 in patients with hematological malignancies: a narrative review and expert insights. Clin Exp Med. 2024;24(1):119. https:\/\/doi.org\/10.1007\/s10238-024-01381-5. Published 2024 Jun 4.","journal-title":"Clin Exp Med"},{"key":"603_CR22","doi-asserted-by":"publisher","first-page":"104886","DOI":"10.1016\/j.ebiom.2023.104886","volume":"98","author":"A Aleman","year":"2023","unstructured":"Aleman A, van Kesteren M, Zajdman AK, et al. Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with multiple myeloma. EBioMedicine. 2023;98:104886. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104886.","journal-title":"EBioMedicine"},{"issue":"1","key":"603_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13027-022-00454-y","volume":"17","author":"G Marcacci","year":"2022","unstructured":"Marcacci G, Coppola N, Madonna E, et al. Post-exposure prophylaxis with sotrovimab for Omicron (B.1.1.529) SARS-CoV-2 variant during the aplastic phase of autologous stem cell transplantation. Infect Agent Cancer. 2022;17(1):41. https:\/\/doi.org\/10.1186\/s13027-022-00454-y. Published 2022 Aug 3.","journal-title":"Infect Agent Cancer"},{"key":"603_CR24","doi-asserted-by":"publisher","unstructured":"Boonyaratanakornkit J, Wang Q, Nader A, et al. The effect of gastrointestinal graft-versus-host disease and diarrhea on the pharmacokinetic profile of sotrovimab in hematopoietic stem cell transplant recipients. J Infect Dis Published Online May. 2024;14. https:\/\/doi.org\/10.1093\/infdis\/jiae236.","DOI":"10.1093\/infdis\/jiae236"},{"key":"603_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/v16020217","volume":"16","author":"D Focosi","year":"2024","unstructured":"Focosi D, Casadevall A, Franchini M, Maggi F, Sotrovimab. A review of its efficacy against SARS-CoV-2 variants. Viruses. 2024;16:217. https:\/\/doi.org\/10.3390\/v16020217.","journal-title":"Viruses"},{"issue":"1","key":"603_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13045-022-01387-0","volume":"15","author":"L Jondreville","year":"2022","unstructured":"Jondreville L, D\u2019Aveni M, Labussi\u00e8re-Wallet H, et al. Pre-exposure prophylaxis with tixagevimab\/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC. J Hematol Oncol. 2022;15(1):169. https:\/\/doi.org\/10.1186\/s13045-022-01387-0. Published 2022 Nov 28.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"603_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/blood.2022018283","volume":"141","author":"JA Davis","year":"2023","unstructured":"Davis JA, Granger K, Roubal K, et al. Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies. Blood. 2023;141(2):200\u20133. https:\/\/doi.org\/10.1182\/blood.2022018283.","journal-title":"Blood"},{"issue":"1","key":"603_CR28","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.amjmed.2022.08.019","volume":"136","author":"MM Al-Obaidi","year":"2023","unstructured":"Al-Obaidi MM, Gungor AB, Kurtin SE, Mathias AE, Tanriover B, Zangeneh TT. The Prevention of COVID-19 in high-risk patients using Tixagevimab-Cilgavimab (Evusheld): real-world experience at a large Academic Center. Am J Med. 2023;136(1):96\u20139. https:\/\/doi.org\/10.1016\/j.amjmed.2022.08.019.","journal-title":"Am J Med"},{"issue":"7","key":"603_CR29","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1007\/s00277-024-05769-x","volume":"103","author":"YJ Lee","year":"2024","unstructured":"Lee YJ, Kim HK, Kim Y, et al. Tixagevimab\/cilgavimab (AZD7442\/Evusheld) prevent from COVID19 in patients with hematologic malignancies under active chemotherapy. Ann Hematol. 2024;103(7):2533\u20139. https:\/\/doi.org\/10.1007\/s00277-024-05769-x.","journal-title":"Ann Hematol"},{"issue":"4","key":"603_CR30","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/ejh.14045","volume":"111","author":"C Callegari","year":"2023","unstructured":"Callegari C, Lazzarotto D, Soravia A, et al. Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination. Eur J Haematol. 2023;111(4):668\u201370. https:\/\/doi.org\/10.1111\/ejh.14045.","journal-title":"Eur J Haematol"},{"key":"603_CR31","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ccell.2022.05.007","volume":"40","author":"R Stuver","year":"2022","unstructured":"Stuver R, Shah GL, Korde NS, Roeker LE, Mato AR, Batlevi CL, et al. The activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer Cell. 2022;40:590\u20131.","journal-title":"Cancer Cell"},{"key":"603_CR32","doi-asserted-by":"publisher","unstructured":"Neofytos D, Khanna N. How I treat: coronavirus disease 2019 in leukemic patients and hematopoietic cell transplant recipients. Transpl Infect Dis Published Online July. 2024;5. https:\/\/doi.org\/10.1111\/tid.14332.","DOI":"10.1111\/tid.14332"},{"issue":"3","key":"603_CR33","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/v15030704","volume":"15","author":"V Spiliopoulou","year":"2023","unstructured":"Spiliopoulou V, Ntanasis-Stathopoulos I, Malandrakis P, et al. Use of oral antivirals ritonavir-nirmatrelvir and Molnupiravir in patients with multiple myeloma is Associated with low rates of severe COVID-19: a Single-Center, prospective study. Viruses. 2023;15(3):704. https:\/\/doi.org\/10.3390\/v15030704. Published 2023 Mar 8.","journal-title":"Viruses"},{"key":"603_CR34","unstructured":"https:\/\/covid.cdc.gov\/covid-data-tracker\/#variant-summary (accessed July 10, 2024)."}],"container-title":["Infectious Agents and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-024-00603-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13027-024-00603-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13027-024-00603-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T10:08:45Z","timestamp":1723457325000},"score":1,"resource":{"primary":{"URL":"https:\/\/infectagentscancer.biomedcentral.com\/articles\/10.1186\/s13027-024-00603-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,12]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["603"],"URL":"https:\/\/doi.org\/10.1186\/s13027-024-00603-5","relation":{},"ISSN":["1750-9378"],"issn-type":[{"type":"electronic","value":"1750-9378"}],"subject":[],"published":{"date-parts":[[2024,8,12]]},"assertion":[{"value":"12 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}}],"article-number":"38"}}